Study guide
13.3 Participant Compensation and Ethics
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
13.3 Participant Compensation and Ethics
Key Takeaways Explain This Topic AI
Compensation must be pro-rated based on study progress to prevent undue influence to remain in a trial.
A clear distinction exists between reimbursing actual expenses and compensating for time and effort.
Vulnerable populations require special ethical considerations to ensure compensation is fair but not coercive.
Last updated: October 2026
- Participant Compensation and Ethics
- The Philosophy of Participant Compensation
In clinical research, participant compensation is a complex ethical landscape. While individuals who volunteer for clinical trials provide immense value to science and society, compensating them must be balanced carefully to avoid coercion or undue influence. Compensation is generally viewed not as a salary or a benefit of the research, but as a reimbursement for time, effort, and expenses incurred. Understanding the ethical boundaries and regulatory frameworks surrounding payment is a fundamental competency for any Clinical Research Coordinator (CRC).
Coercion vs. Undue Influence
To navigate compensation ethics, one must distinguish between coercion and undue influence, concepts frequently emphasized by Institutional Review Boards (IRBs) and the Office for Human Research Protections (OHRP).
Coercion occurs when an overt threat of harm is intentionally presented by one person to another in order to obtain compliance. For example, a physician telling a patient that they will lose access to standard clinic care if they do not enroll in a trial is coercive.
Undue Influence occurs through an offer of an excessive, unwarranted, inappropriate, or improper reward or other overture in order to obtain compliance. If a trial offers $10,000 for a minor, low-risk outpatient study, the amount might unduly influence a financially vulnerable individual to participate against their better judgment, blinding them to potential risks.
IRBs carefully review all compensation plans to ensure that the payment amount and the proposed method of disbursement do not present undue influence.
Structuring Compensation Plans
A well-designed compensation plan aligns with the time and burden of the study without serving as the primary incentive for participation.
Pro-Rated Payments
Compensation must accrue as the study progresses and should not be contingent upon the participant completing the entire study. This is a critical ethical safeguard. If a study requires 10 visits and pays $1,000, it is unethical to withhold all payment until Visit 10. Such a structure would compel participants who wish to withdraw early (e.g., due to side effects) to remain in the trial solely to receive the money. Instead, payments should be pro-rated, such as $100 per completed visit.
Completion Bonuses
While modest completion bonuses are sometimes acceptable, they must not be so large that they become coercive. For example, a structure paying $50 per visit for 9 visits, and a $500 bonus for the final visit, would likely be flagged by an IRB as undue influence because the disproportionate final payment might pressure a participant to stay in the study against their will.
Reimbursement for Expenses
Distinct from compensation for time and effort, reimbursement covers actual out-of-pocket expenses incurred by the participant. This commonly includes:
- Mileage or public transit costs
- Parking fees
- Lodging and meals (for trials requiring long travel or overnight stays)
Reimbursements are generally viewed favorably by IRBs as they remove logistical and financial barriers to participation, particularly aiding diverse and lower-income populations in accessing clinical trials.
Type of Payment Description Ethical Considerations
Time and Effort Flat fee per visit or per hour Must be reasonable for the demographic; not so high as to induce participation despite risks.
Expense Reimbursement Covering parking, travel, meals Highly encouraged to ensure equity; should be based on actual costs or standard mileage rates.
Completion Bonus Extra payment at the end of the study Must be minimal compared to total compensation; cannot force participants to endure unwanted side effects.
Methods of Disbursement
The logistical handling of compensation is typically managed by the CRC or the site's financial department. Modern clinical trials have largely shifted away from petty cash and checks toward more secure and traceable methods.
ClinCard and Prepaid Debit Cards
Many sponsors utilize prepaid debit card systems, such as the Greenphire ClinCard. These systems allow CRCs to load funds directly onto a participant's card immediately following a completed visit. This method provides instant gratification, reduces the administrative burden on the site's accounting department, and creates a clear, auditable electronic trail of all disbursements.
IRS Reporting Requirements
CRCs must be aware of tax implications for participants. In the United States, the IRS considers compensation for clinical trial participation to be taxable income (note: expense reimbursements are generally not taxable). For payments made in 2026 or later, if a participant receives $2,000 or more from a single institution in a calendar year, the institution is required to issue an IRS Form 1099-MISC (the threshold was $600 before 2026 and may be adjusted for inflation from 2027). Participants must be informed of this possibility during the informed consent process, as it may affect their willingness to participate or impact government assistance benefits they receive.
Vulnerable Populations and Compensation
Special consideration must be given when compensating vulnerable populations, such as children, prisoners, or individuals with cognitive impairments.
Pediatric Studies: Compensation is often split. The parent or guardian may receive reimbursement for travel and time away from work, while the child receives a small, age-appropriate token of appreciation (e.g., a $15 gift card to a toy store or a movie ticket). Large cash payments to parents for their child's participation are heavily scrutinized as they may unduly influence the parent to enroll the child in a risky study.
Economically Disadvantaged: IRBs often debate whether standard compensation amounts are unduly influential for low-income populations. The general consensus is that compensation should not be reduced simply because a population is poor, as this would be exploitative. Instead, the focus remains on ensuring the risks are reasonable and clearly communicated.
Best Practices for CRCs
Clear Documentation: Ensure the compensation schedule is explicitly detailed in the IRB-approved Informed Consent Form (ICF).
Timely Disbursement: Process payments immediately after visits to maintain trust and protocol compliance.
Transparent Communication: Explain the pro-rated nature of the payments and potential tax implications during the consent discussion.